2002
DOI: 10.1016/s0360-3016(02)02834-1
|View full text |Cite
|
Sign up to set email alerts
|

Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers’ experience

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

7
67
1
14

Year Published

2004
2004
2012
2012

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 120 publications
(89 citation statements)
references
References 71 publications
7
67
1
14
Order By: Relevance
“…16 In retrospective series, younger age also has been identified as a risk factor for ipsilateral recurrence. [34][35][36][37][38] Our data confirm these findings: younger patients (<50 years) were more likely to develop a local recurrence. This age difference could not be attributed to different treatment strategies: no difference in mean age was found in the mastectomy and breast-conserving surgery groups.…”
Section: Discussionsupporting
confidence: 86%
“…16 In retrospective series, younger age also has been identified as a risk factor for ipsilateral recurrence. [34][35][36][37][38] Our data confirm these findings: younger patients (<50 years) were more likely to develop a local recurrence. This age difference could not be attributed to different treatment strategies: no difference in mean age was found in the mastectomy and breast-conserving surgery groups.…”
Section: Discussionsupporting
confidence: 86%
“…However, this rate was much higher (58%) in a large series from the Netherlands Cancer Institute (Meijnen et al, 2008). Tumour Table 3 Influence of tumour size, nuclear grade, necrosis and age on treatment modality (number and percent patients) (Fisher et al, 2001;Solin et al, 2001;Cutuli et al, 2002;Fourquet et al, 2002;Vicini and Recht, 2002;Bijker et al, 2006). These data probably explain our 50% mastectomy rates in women under the age of 40 years.…”
Section: Discussionmentioning
confidence: 87%
“…In four randomized controlled trials, the LR rates after CS without RT were 32, 28, 26 and 22%, with follow-ups ranging from 52 to 120 months (Fisher et al, 2001;Hougton et al, 2003;Bijker et al, 2006;Holmberg et al, 2008). In a French study, the 7-year LR rate was 32.4% in patients not receiving RT (Cutuli et al, 2002). In two latest Dutch studies (Schouten Van Der Velden et al, 2007;Meijnen et al, 2008), the 8-and 10-year LR Survey of DCIS in France B Cutuli et al after CS alone were 15.6 and 25%, respectively.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…(Fisher, 1993), cosa que ha bajado la tasa de recidivas locales a un 8-15 % a los 10 años, en relación a la calidad de la exéresis quirúrgica, de la edad del paciente, el grado, y los sub-tipos histológicos. Los trials randomizados (exclusivos para los CCIS) National Surgical Adjuvant Breast and Bowel Project B17 (NSABP B-17), y European Organization for Research and Treatment of Cancer (EORTC) 10853 han comparado la tumorectomía versus la tumorectomía + radioterapia (50 Gy en un booster), y un trabajo multicéntrico retrospectivo francés (Cutuli, 2002) confirmó los beneficios de la irradiación después de la tumorectomía (sin modificación de la sobrevida).…”
Section: Standard De La Radioterapia En El Carcinoma In Situunclassified